These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 33724679)

  • 21. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
    Hartman ML; Sztiller-Sikorska M; Gajos-Michniewicz A; Czyz M
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting of PDGF-C/NRP-1 autocrine loop as a new strategy for counteracting the invasiveness of melanoma resistant to braf inhibitors.
    Ruffini F; Ceci C; Atzori MG; Caporali S; Levati L; Bonmassar L; Cappellini GCA; D'Atri S; Graziani G; Lacal PM
    Pharmacol Res; 2023 Jun; 192():106782. PubMed ID: 37127213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma.
    Feddersen CR; Schillo JL; Varzavand A; Vaughn HR; Wadsworth LS; Voigt AP; Zhu EY; Jennings BM; Mullen SA; Bobera J; Riordan JD; Stipp CS; Dupuy AJ
    Cancer Res; 2019 Oct; 79(19):5074-5087. PubMed ID: 31416844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC).
    Alves-Fernandes DK; Oliveira ÉA; Faião-Flores F; Alicea-Rebecca G; Weeraratna AT; Smalley KSM; Barros SBM; Maria-Engler SS
    Pharmacol Res; 2019 Mar; 141():63-72. PubMed ID: 30550954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.
    Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK
    J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway.
    Gupta R; Bugide S; Wang B; Green MR; Johnson DB; Wajapeyee N
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4583-4591. PubMed ID: 30782837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAFi induced demethylation of miR-152-5p regulates phenotype switching by targeting TXNIP in cutaneous melanoma.
    Li K; Tang M; Tong S; Wang C; Sun Q; Lv M; Sun X; Wang T; Jin S
    Apoptosis; 2020 Apr; 25(3-4):179-191. PubMed ID: 32056038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAF
    Jandova J; Park SL; Corenblum MJ; Madhavan L; Snell JA; Rounds L; Wondrak GT
    Mol Carcinog; 2022 Jun; 61(6):603-614. PubMed ID: 35417045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification.
    Dugo M; Nicolini G; Tragni G; Bersani I; Tomassetti A; Colonna V; Del Vecchio M; De Braud F; Canevari S; Anichini A; Sensi M
    Oncotarget; 2015 Mar; 6(7):5118-33. PubMed ID: 25742786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AXL inhibition improves BRAF-targeted treatment in melanoma.
    Nyakas M; Fleten KG; Haugen MH; Engedal N; Sveen C; Farstad IN; Flørenes VA; Prasmickaite L; Mælandsmo GM; Seip K
    Sci Rep; 2022 Mar; 12(1):5076. PubMed ID: 35332208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells.
    Faião-Flores F; Alves-Fernandes DK; Pennacchi PC; Sandri S; Vicente AL; Scapulatempo-Neto C; Vazquez VL; Reis RM; Chauhan J; Goding CR; Smalley KS; Maria-Engler SS
    Oncogene; 2017 Mar; 36(13):1849-1861. PubMed ID: 27748762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversing vemurafenib-resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects.
    Fragale A; Stellacci E; Romagnoli G; Licursi V; Parlato S; Canini I; Remedi G; Buoncervello M; Matarrese P; Pedace L; Ascione B; Pizzi S; Tartaglia M; D'Atri S; Presutti C; Capone I; Gabriele L
    Int J Cancer; 2023 Sep; 153(5):1080-1095. PubMed ID: 37293858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma.
    Li YY; Wu C; Chen SM; Shah SS; Wangpaichitr M; Feun LG; Kuo MT; Suarez M; Prince J; Savaraj N
    Oncotarget; 2016 Apr; 7(14):17665-80. PubMed ID: 26771234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma.
    Tian Y; Guo W
    Med Sci Monit; 2020 Apr; 26():e920957. PubMed ID: 32273491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition.
    Sharma R; Fedorenko I; Spence PT; Sondak VK; Smalley KS; Koomen JM
    J Proteome Res; 2016 Dec; 15(12):4476-4489. PubMed ID: 27934295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma.
    Audrito V; Managò A; La Vecchia S; Zamporlini F; Vitale N; Baroni G; Cignetto S; Serra S; Bologna C; Stingi A; Arruga F; Vaisitti T; Massi D; Mandalà M; Raffaelli N; Deaglio S
    J Natl Cancer Inst; 2018 Mar; 110(3):. PubMed ID: 29309612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas.
    Wang J; Huang SK; Marzese DM; Hsu SC; Kawas NP; Chong KK; Long GV; Menzies AM; Scolyer RA; Izraely S; Sagi-Assif O; Witz IP; Hoon DSB
    J Invest Dermatol; 2015 Feb; 135(2):532-541. PubMed ID: 25243790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.
    Zhu G; Yi X; Haferkamp S; Hesbacher S; Li C; Goebeler M; Gao T; Houben R; Schrama D
    Cancer Lett; 2016 Jun; 376(1):43-52. PubMed ID: 27000992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas.
    Garandeau D; Noujarède J; Leclerc J; Imbert C; Garcia V; Bats ML; Rambow F; Gilhodes J; Filleron T; Meyer N; Brayer S; Arcucci S; Tartare-Deckert S; Ségui B; Marine JC; Levade T; Bertolotto C; Andrieu-Abadie N
    Mol Cancer Ther; 2019 Feb; 18(2):289-300. PubMed ID: 30482853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteogenomics Reveals Perturbed Signaling Networks in Malignant Melanoma Cells Resistant to BRAF Inhibition.
    Schmitt M; Sinnberg T; Bratl K; Zittlau K; Garbe C; Macek B; Nalpas NC
    Mol Cell Proteomics; 2021; 20():100163. PubMed ID: 34673281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.